EphemerisXResearch

Complete Response Letters

Zhejiang Novus Pharmaceuticals Co. Ltd.: Vancomycin Hydrochloride

What FDA's Complete Response Letters to the company say, in the letters' own words.

Complete Response Letter, Aug 25, 2021

Drug, and Cosmetic Act for Vancomycin Hydrochloride for Injection, 500 mg/vial, 1 gram/vial, 5 gram/vial, and 10 gram/vial.
Complete Response Letter · Aug 25, 2021 · p. 2Open the letter at p. 2 ↗CRL_NDA210274_20210825:p1:s12

Complete Response Letter, Nov 27, 2020

Pharmaceuticals Co., Ltd. FEI: 3013567704 manufacturing facility at Zhejiang, China, for this application, our field investigator observed objectionable conditions at the facility and conveyed that information to the representative of the facility at the close of the inspection.
Complete Response Letter · Nov 27, 2020 · p. 2Open the letter at p. 2 ↗CRL_NDA210274_20201127:p1:s19
Satisfactory resolution of the remaining objectionable conditions, and verification by the FDA, is required before this application may be approved.
Complete Response Letter · Nov 27, 2020 · p. 2Open the letter at p. 2 ↗CRL_NDA210274_20201127:p1:s20
In any resubmission of this application, please submit revised draft carton and container labeling that contains the following revisions:
Complete Response Letter · Nov 27, 2020 · p. 3Open the letter at p. 3 ↗CRL_NDA210274_20201127:p1:s44

Complete Response Letter, Jun 15, 2018

Please note the amendments dated May 11, 2018 and May 25, 2018, were not reviewed during this review cycle.
Complete Response Letter · Jun 15, 2018 · p. 12Open the letter at p. 12 ↗CRL_NDA210274_20180615:p1:s16

More Complete Response Letters

All companies in the CRL Tracker →

Updated Sep 30, 2026 · built from 283 companies in the EphemerisX knowledge graph. This page is regenerated as companies are added.